微信扫码关注“小狗文献”

即刻体验更多权益

文献多,下载快,翻译准

首页 > 医学词汇大全 > Erlotinib
Erlotinib

肿瘤

关键词肿瘤 药物 肺癌

词汇介绍

拓展阅读

解析

Erlotinib

释    义   n. 埃罗替尼;厄洛替尼;特罗凯

例    句   By inhibition of phosphorylation of tyrosine kinase, erlotinib blocks the EGFR tyrosine kinase protein in the cancer cell from getting a message that tells the cell to grow and divide. 盐酸埃罗替尼是一种小分子表皮生长因子酪氨酸激酶可逆抑制剂,通过抑制酪氨酸激酶的磷酸化,阻断信号传导,抑制肿瘤生长。

概述

厄洛替尼是一个酪氨酸激酶抑制剂(TKI),可逆性的抑制特定类型的EGFR突变。EGFR(表皮生长因子受体)存在于人体正常细胞和癌细胞表面,与细胞的生长及复制息息相关。吉非替尼抑制EGFR,可以阻断依赖EGFR的细胞的增殖,达到抑制肿瘤细胞生长的目的。2013年5月14日,美国食品药品监督管理局(FDA)批准了厄洛替尼(Tarceva®,安斯泰来制药公司)用于一线治疗转移性非小细胞肺癌(NSCLC)。这些转移性NSCLC患者的一个重要特征是肿瘤组织的EGFR第19个外显子存在缺失突变或第21个

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial复制标题

Ramuciromab联合厄洛替尼治疗未经治疗、EGFR突变的晚期非小细胞肺癌 (RELAY): 一项随机、双盲、安慰剂对照、3期临床试验

发表时间:2019-10-04

影响因子:35.4

作者: Kazuhiko Nakagawa

期刊:Lancet Oncol.

Between Jan 28, 2016, and Feb 1, 2018, 449 eligible patients were enrolled and randomly assigned to treatment with ramucirumab plus erlotinib (n=224) or placebo plus erlotinib (n=225). Median duration of follow-up was 20.7 months (IQR 15.8-27.2). At the time of primary analysis, progression-free survival was significantly longer in the ramucirumab plus erlotinib group (19.4 months [95% CI 15.4-21.6]) than in the placebo plus erlotinib group (12.4 months [11.0-13.5]), with a stratified hazard ratio of 0.59 (95% CI 0.46-0.76; p<0.0001). Grade 3-4 treatment-emergent adverse events were reported in 159 (72%) of 221 patients in the ramucirumab plus erlotinib group versus 121 (54%) of 225 in the placebo plus erlotinib group. The most common grade 3-4 treatment-emergent adverse events in the ramucirumab plus erlotinib group were hypertension (52 [24%]; grade 3 only) and dermatitis acneiform (33 [15%]), and in the placebo plus erlotinib group were dermatitis acneiform (20 [9%]) and increased alanine aminotransferase (17 [8%]).

译文

在2016年1月28日至2018年2月1日之间,纳入449例合格患者,并随机分配接受雷莫昔单抗加厄洛替尼(n = 224)或安慰剂加厄洛替尼(n = 225)治疗。中位随访时间为20.7个月(IQR 15.8-27.2)。在初步分析时,雷莫昔单抗联合厄洛替尼组的无进展生存期(19.4个月[95%CI 15.4-21.6])比安慰剂联合厄洛替尼组的无进展生存期(12.4个月[11.0-13.5])明显更长。分层风险比为0.59(95%CI 0.46-0.76; p <0.0001)。雷莫昔单抗加厄洛替尼组的221名患者中有159名(72%)发生了3-4级治疗紧急事件,而安慰剂加厄洛替尼组的225名中有121名(54%)。雷莫昔单抗联合厄洛替尼组最常见的3-4级治疗发生不良事件为高血压(52 [24%];仅3级)和痤疮性皮肤炎(33 [15%]),而安慰剂联合厄洛替尼组为痤疮皮炎(20 [9%])和丙氨酸转氨酶升高(17 [8%])。